A Swiss-based biotech company announced that it has developed a vaccine called HypoCat that works by “immunizing cats against their own major allergen” which is known as Fel d 1.
Their findings were published by The Journal of Allergy and Clinical Immunology.
The Fel d 1 allergen is found in cat dander, and approximately 10% of people in the Western world are allergic to it.
“Our HypoCat vaccine is able to produce high levels of antibodies in cats,” HypoPet CEO Gary Jennings said in a statement. “These antibodies can bind and neutralize the Fel d 1 allergen produced by the animals.”
The vaccine was “well tolerated without any overt toxicity” by the 54 cats tested during a total of four studies.
Get the full story at nydailynews.com.